Background: Most studies investigating the benefits of statins have focused on North
American and European populations. This study focuses on evaluating the lipid-lowering …

The reduction in LDL cholesterol (c-LDL) is one of the main objectives in cardiovascular
prevention. Multiple clinical studies have demonstrated the benefit of lowering c-LDL …

Both the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III
and the Second Joint Task Force of European Societies guidelines have established low …

Aims: Rosuvastatin is more efficacious than other statins in lowering low-density lipoprotein
cholesterol (LDL-C). Studies showing higher blood levels in Asians have resulted in …

Background: A statin alone or non-statins as add-ons have been introduced to intensive low-
density lipoprotein cholesterol (LDL-C)-lowering therapy in patients at risk for high …

Background Reducing low-density lipoprotein cholesterol (LDL-C) levels decreases
cardiovascular risk in direct proportion to the decrease in LDL-C. Design The aim of this …

Background: Patients at high risk of cardiovascular disease frequently fail to reach
recommended low-density lipoprotein cholesterol (LDL-C) goals, partly because statin …

Increased LDL cholesterol is the main risk factor for cardiovascular (CVD) diseases,
particularly coronary heart disease (CHD) and myocardial infarction (MI). The treatment of …

The American College of Cardiology and American Heart Association (ACC/AHA)
guidelines identified four statin benefit groups on the basis of atherosclerotic cardiovascular …

Background High intensity statins such as rosuvastatin and atorvastatin are the main lipid
lowering agents for patients with cardiovascular diseases (CVD), however the efficacy …